Spruce Bio is conducting the CAHmelia-204 clinical trial evaluating its wholly-owned candidate, tildacerfont, a CRF1 receptor antagonist, for the treatment of adults with classic congenital adrenal hyperplasia (CAH). Spruce is also conducting a Phase 2 trial in pediatric patients with classic CAH.

The CAHmelia clinical trial evaluating tildacerfont in adults with classic CAH has completed enrollment. To learn more, please visit sprucebio.com/cahmelia.

For more information on the ongoing trials in adult and pediatric patients with classic CAH, and in women with PCOS, please visit clinicaltrials.gov